PD-L1, PD1,TMB and Lung Cancer | American Lung Association
2024年10月2日 · PD-L1 and TMB are biomarkers that may help provide information about whether or not a patient will benefit from immunotherapy to treat their lung cancer. What are PD-L1 and PD-1? Immunotherapy activates the immune system to attack cancer cells. The most common type of lung cancer immunotherapy is called an immune checkpoint inhibitor. Several ...
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
2015年5月21日 · We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non–small-cell lung cancer enrolled in a phase 1 study.
Regulatory mechanisms of PD-1/PD-L1 in cancers - Molecular Cancer
2024年5月18日 · Blockade of PD-1/PD-L1 by neutralizing antibodies restores T cells activity and enhances anti-tumor immunity, achieving remarkable success in cancer therapy. Therefore, the regulatory mechanisms of PD-1/PD-L1 in cancers have attracted an increasing attention.
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung ...
Two independent clinical trials looked at whether dialing down inflammation using drugs called JAK inhibitors could improve the efficacy of anti–PD-1 immunotherapy in cancer patients (see the Perspective by Gadina and O’Shea).
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
2018年4月16日 · Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non–small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a...
PD-L1 Expression in Lung Cancer - PMC - PubMed Central (PMC)
Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein expression has emerged as a biomarker that predicts which patients are more likely to respond to immunotherapy.
The miRNA and PD-1/PD-L1 signaling axis: an arsenal of ... - Nature
2024年9月29日 · Specifically, we examine how altering the miRNA profile can impact the activity of various immune checkpoint inhibitors, focusing on the PD-1/PD-L1 pathway within the complex landscape of...
PD-1 and PD-L1 in cancer immunotherapy: clinical implications …
Here, we review the structure of PD-1 and PD-L1, the function of the PD-1/PD-L1 signaling pathway, the application of PD-1 or PD-L1 monoclonal antibodies and future directions for anti-PD-1/PD-L1 antibodies with combination therapies.
PD-1/PD-L1 axis in lung cancer - PMC - PubMed Central (PMC)
The rapid development of anti-PD-1/PD-L1 inhibitors for treatment of advanced NSCLC has profoundly improved the outcomes for patients, revealed critical new biology about lung cancer and immunity, and initiated a booming opportunity for drug development.
Mechanisms regulating PD-L1 expression in cancers and ... - Nature
2022年2月7日 · Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve patient...